Clinical Trials Directory

Trials / Completed

CompletedNCT04132050

A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788

A Phase III Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
34 (actual)
Sponsor
Kissei Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the efficacy, safety and pharmacokinetics of R788 compared with placebo, and to investigate the safety and efficacy of long term dosing of R788 in patients with chronic idiopathic thrombocytopenic purpura.

Conditions

Interventions

TypeNameDescription
DRUGR788Oral administration
DRUGPlaceboOral administration

Timeline

Start date
2019-12-24
Primary completion
2021-12-21
Completion
2023-09-25
First posted
2019-10-18
Last updated
2025-08-11
Results posted
2025-08-11

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT04132050. Inclusion in this directory is not an endorsement.

A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 (NCT04132050) · Clinical Trials Directory